All In Biotech

Drug Trial Radar · NCT06746519

BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

A Phase I/II , Multicenter, Open Label Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of the Combination of the Menin Inhibitor BN104 for the Treatment of Patients With Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Dec 25, 2024

Primary completion

Dec 30, 2025

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Chen SuningAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioNova Pharmaceuticals (Shanghai) LTD.
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken twice daily combined with Intensive Chemotherapy or Venetoclax/Azacitidine in patients with acute myeloblastic leukemia.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • BN104 combined Intensive Chemotherapy or Venetoclax/AzacitidineDrug

    The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of BN104 in combination with Venetoclax/Azacitidine or intensive chemotherapyTime frame: At the end of Cycle1 (Cycle1 Day28)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.